HCM
NEUTRALHUTCHMED Announces China Approval for ORPATHYS® and TAGRISSO® Combination in Lung Cancer
The healthcare company has received approval in China for a new lung cancer treatment combination.
HUTCHMED (China) Limited
223.00GBX
-1.76%
Market Cap
1.91B
Volume
2.92k
5% of avg
P/E Ratio
74.33
EPS (TTM)
0.03
Beta
0.61
Day Range
217.90p - 227.00p
52 Week Range
185.50p223.00p336.00p
223.00p
Upcoming Events
September 2025
NDA filings for fruquintinib and sintilimab combination in advanced RCC
High Impact Event
HCM
NEUTRALHUTCHMED Grants Share Options and LTIP Awards to Executives
The healthcare company has granted share options and LTIP awards to its executive team as part of its compensation and retention strategy.
HCM
GOODHUTCHMED and Innovent Announce NDA Acceptance for Fruquintinib and Sintilimab Combination in Renal Cell Carcinoma
The biopharmaceutical company has announced that its NDA for a combination therapy to treat advanced renal cell carcinoma has been accepted for review, marking a key milestone in bringing this potential new treatment option to patients.
HCM
NEUTRALHUTCHMED Highlights Positive SACHI Phase III Data for Savolitinib and Osimertinib Combination in NSCLC
The biopharmaceutical company has announced positive results from a Phase III study of its savolitinib and osimertinib combination therapy for NSCLC patients.
HCM
NEUTRALHUTCHMED Highlights Data to be Presented at ASCO
The biopharmaceutical company HUTCHMED announces that new data from several studies of its compounds will be presented at the upcoming ASCO Annual Meeting.
HCM
NEUTRALHUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
The biopharmaceutical company HUTCHMED announces data from several studies of its compounds, including savolitinib, fruquintinib and surufatinib, to be presented at the upcoming AACR Annual Meeting 2025.
HCM
NEUTRALHUTCHMED Completes Enrollment of Phase II Gastric Cancer Study
The biopharmaceutical company has completed enrollment for a Phase II study evaluating its drug savolitinib in treating gastric cancer patients with MET amplification.
HCM
NEUTRALHUTCHMED Announces 2024 Annual Report and Notice of AGM
The biopharmaceutical company has released its 2024 Annual Report and announced the details of its upcoming Annual General Meeting.
HCM
GOODHUTCHMED Receives NMPA Conditional Approval for TAZVERIK® in Relapsed or Refractory Follicular Lymphoma
The biopharmaceutical company receives conditional approval from China's NMPA for its TAZVERIK® treatment for relapsed or refractory follicular lymphoma, marking an important milestone in expanding its product portfolio.
HCM
NEUTRALHUTCHMED Announces Retirement of Independent Non-executive Directors
The healthcare company announces the retirement of two long-serving independent directors from its board.